Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Kevin Lee M.B.A., Ph.D. | CEO & Executive Director | 1.3M | -- | 1968 |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE | Co-Founder & Non-Executive Director | 55.55k | -- | 1951 |
| Ms. Alethia Rene Young | Chief Financial Officer | 559.52k | -- | 1980 |
| Dr. Santiago Arroyo M.D., Ph.D. | Chief Development Officer | 882.03k | -- | 1960 |
| Dr. Christian Heinis | Scientific Founder | -- | -- | -- |
| Mr. Alistair Milnes | Chief Operating Officer | 765.75k | -- | 1974 |
| Mr. Travis Thompson | Senior VP, Chief Accounting Officer & Principal Accounting Officer | -- | -- | -- |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Technology Officer | 847.43k | -- | 1969 |
| Ms. Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications | -- | -- | -- |
| Mr. Zafar Qadir | Chief Legal Officer & General Counsel | -- | -- | -- |
Bicycle Therapeutics plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 284
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Corporate Governance
Upcoming Events
February 18, 2025 at 1:30 PM UTC - February 24, 2025 at 1:30 PM UTC
Bicycle Therapeutics plc Earnings Date
Recent Events
Recent Events Information Not Available